Clinical trial

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

NCT05315700

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-03-10

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2022-03-10Date precision: day

Registry last updated2026-09-04

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Solid Tumorsunresolved

Interventions

ORIC-114DRUG

Chemotherapy drugDRUG

Sponsors & collaborators

ORIC Pharmaceuticalslead sponsor

Mapped research locations

SeoulSouth Korea3 BarcelonaSpain2 Kuala LumpurMalaysia2 New YorkNew York, United States1 BostonMassachusetts, United States1 ChicagoIllinois, United States1 PhiladelphiaPennsylvania, United States1 TorontoOntario, Canada1 San FranciscoCalifornia, United States1 MadridSpain1 TampaFlorida, United States1 DurhamNorth Carolina, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05315700 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.